Molecular Oncology Almanac
  • API
  • Approvals
  • Organizations
  • About
  • Contact

Lapatinib

About

Therapy type: Targeted therapy

Therapy strategy: HER2 inhibition

Mappings

NCI Thesaurus: Lapatinib (ncit:C26653)

Therapeutic response

Precision oncology relationships for therapeutic response involving this therapy.

Type Biomarker(s) Cancer type Therapy(ies)
Sensitivity (+) HER2-positive Invasive Breast Carcinoma Capecitabine, Lapatinib
Sensitivity (+) ER positive, HER2-positive Invasive Breast Carcinoma Lapatinib, Letrozole
Sensitivity (+) HER2-positive, PR positive Invasive Breast Carcinoma Lapatinib, Letrozole
Sensitivity (+) ER positive, HER2-positive, PR positive Invasive Breast Carcinoma Lapatinib, Letrozole
Sensitivity (+) HER2-positive Invasive Breast Carcinoma Capecitabine, Lapatinib
Sensitivity (+) ERBB2 amplification Invasive Breast Carcinoma Capecitabine, Lapatinib
Sensitivity (+) ER positive, HER2-positive, PR negative Invasive Breast Carcinoma Lapatinib, Trastuzumab
Sensitivity (+) ER positive, ERBB2 amplification, PR negative Invasive Breast Carcinoma Lapatinib, Trastuzumab
Sensitivity (+) ER positive, HER2-positive, PR positive Invasive Breast Carcinoma Lapatinib, Letrozole
Sensitivity (+) ER positive, ERBB2 amplification, PR positive Invasive Breast Carcinoma Lapatinib, Letrozole
Sensitivity (+) HER2-positive Invasive Breast Carcinoma Capecitabine, Lapatinib

Please review our privacy policy and terms before use.
API | Bluesky | Contact | GitHub

  • Dana-Farber logo
  • University of Limerick Digital Health Center logo
  • eHealthHub logo